Business

Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders

Jaguar to report pivotal phase 3 OnTarget trial results for its cancer supportive care drug crofelemer on or before July 23, 2024Investor webcast on or before

articleJaguar Health, Inc.June 21, 20245/company/jaguar-animal-health-inc/news/jaguar-health-reports-approval-of-all-proposals-at-june-2024-annual-meeting-of-stockholders
Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders

About this update from Jaguar Health, Inc.

[{"type":"text","content":"Jaguar to report pivotal phase 3 OnTarget trial results for its cancer supportive care drug crofelemer on or before July 23, 2024Investor webcast on or before July 23 will include updates on Jaguar's cancer supportive care portfolio, including participation from Jaguar scientific team, patient advocates, and leading oncology experts on cancer therapy-related diarrhea and oral mucositisIn honor of World Rainforest Day (June 22), Jaguar is proud to share RealPharma podcast interview with ethnobotanist Dr. Steven King SAN FRANCISCO, CA / ACCESSWIRE / June 21, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (\"Jaguar\" or the \"Company\") today announced the voting results of the Company's Annual Meeting of Stockholders held June 21, 2024 (the \"Annual Meeting\").Five proposals were submitted to and approved by the stockholders of the Company at the Annual Meeting. The proposals are described in detail in the Company's definitive proxy statement on Schedule 14A relating to the Annual Meeting on May 21, 2024 and supplemental information filed with the Securities and Exchange Commission. Stockholders may obtain a free copy of the proxy statement and other documents filed by Jaguar with the SEC at http://www.sec.gov. The proxy statement is also available on the Company's corporate website.\"In honor of World Rainforest Day (June 22), we are proud to share the link to RealPharma's recent podcast interview with ethnobotanist Steven King, PhD, Jaguar's Chief Sustainable Supply, Ethnobotanical Research, and IP Officer,\" said Lisa Conte, the Company's founder, president and CEO. \"The RealPharma podcast series is hosted by Dr. Na-Ri Oh and Ian Wendt, Jaguar's Chief Commercial Officer. In the interview, Dr. King shares incredible stories from his journey - like living with indigenous communities in the Amazon and learning about their medicinal uses of plants. He also discusses the powerful impact these natural resources can have on global health, all while preserving the cultures that discovered them. It's a testament to how ancient wisdom and cutting-edge science can work hand-in-hand. The podcast episode can be accessed at this link: From the Forest to your Pharmacy: Dr. Steven King's Ethnobotanical Journey.\"About the Jaguar Health Family of CompaniesJaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developin...

More updates from Jaguar Health, Inc.